A previous NMA has compared all first-line treatments for advanced EGFR-mutated NSCLC patients, and found that gefitinib + pemetrexed-based chemotherapy and osimertinib might be the optimal therapy with the greatest benefits in PFS and OS [23]. Here, EGFR is linked to non-small cell lung carcinoma.